Navigation Links
Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
Date:6/30/2008

- Product appears safe with no dose-limiting toxicities -

- Chemophase dose for pivotal trials successfully determined - - Halozyme to seek input from regulatory authorities in order to advance

into pivotal clinical program in 2009 -

SAN DIEGO, June 30 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced a status update for its continuing Phase I/IIa Chemophase(R) clinical trial in the treatment of superficial bladder cancer. Based on the results, the Chemophase combination treatment of mitomycin plus the recombinant human hyaluronidase (rHuPH20) enzyme was well tolerated and appears safe. The study reported no dose-limiting toxicities and no observed side effects attributable to the enzyme, and established the dose for subsequent clinical trials, therefore achieving the pre-defined primary objective of the study. In addition, there were no neutralizing antibodies to rHuPH20 detected and the plasma concentration of mitomycin was either non-measureable or negligible and well below the threshold that may be predictive for myelosuppression (a decrease in bone marrow activity, resulting in fewer red blood cells, white blood cells, and platelets).

The study also provided support for future pivotal trial development that will incorporate the highest combination dose studied in the current trial, mitomycin plus 800,000 Units of rHuPH20. Commenting on the results, Richard C. Yocum, M.D., Vice President of Clinical Development and Medical Affairs at Halozyme stated, "We are pleased the study demonstrated that Chemophase was well-tolerated and produced no dose-limi
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
2. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
3. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
4. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
5. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
6. Data Presented at American Headache Societys Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics Tezampanel
7. TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate
8. CV Therapeutics Announces Archives of Internal Medicine Publication of Study Showing 20 Percent of Heart Attack Patients in Premier Registry Experienced Angina at One Year
9. Pilot Therapeutics Announces Relaunch as Gene Smart(TM) Health
10. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
11. PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Fla. , Jan. 23, 2015  Today the U.S. ... Novartis, Bexsero® for the prevention of serogroup B ... Bexsero and Pfizer,s vaccine Trumenba®, which received FDA approval ... prevent this devastating disease. "I have ...
(Date:1/23/2015)... , Jan. 23, 2015  The Partnership to Fight Chronic Disease (PFCD) ... health care leaders and a new study analyzing the impact of ... is a nationwide coalition working to educate policy makers and the ... the Capitol was focused on how the Iowa ...
(Date:1/23/2015)... Jan. 23, 2015 More than a third of reproductive-aged ... those with private insurance, filled a prescription for an opioid ... in this week,s Morbidity and Mortality Weekly Report (MMWR). ... to treat moderate to severe pain.  They are also found ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3
... , MORRISVILLE, N.C., Nov. 16 nContact Surgical, Inc. ... non-invasive treatment for heart conditions, today announced the initiation ... and efficacy of its Numeris® - AF ... open-chest concomitant procedure for the treatment of longstanding persistent ...
... , WALTHAM, Mass., Nov. ... research and advisory firms for pharmaceutical and healthcare issues, ... the methicillin-resistant Staphylococcus aureus (MRSA) drug market ... three emerging agents from Theravance/Astellas, Johnson & Johnson/Basilea and ...
Cached Medicine Technology:nContact Announces Initiation of Clinical Trials for the Treatment of Atrial Fibrillation in Open-Chest Procedures 2Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018 2Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018 3
(Date:1/22/2015)... Padre Murphy's and Owner Tom Boyle in Glendale, ... Health Alliance (PPHA). The PPHA's passion for others' well-being ... NFL greats, treated for obstructive sleep apnea (OSA) has propelled ... cause in the valley. The most recent plans for an ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Blue Cross and ... Minnesotans who exemplify what it means to “Live Fearless.” ... for people to share their stories about how they or ... simply inspired others by living in the moment. By telling ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A new ... of experience and person-centeredness in the long-term care environment ... action across the continuum. The paper, “The Power of ... engages perspectives and practices of the patient, resident and ...
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post presenting ... . , Purchasing an accidental death and dismemberment rider ... type of rider provides benefits if the insured dies in ... lesser form of life insurance. , AD&D is not ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne ... highest annual revenues in the past three years. Today, the ... dresses. , According to the sales manager of the company, ... them in 2015. This point can be reflected on the ...
Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2
... four private companies took over the reins of the contract, ... huge problems for patients for whom oxygen supply can mean ... about 60,000 people are in need of oxygen at home ... of Oxygen have taken a beating. A woman reportedly died ...
... survey reported an increased level of mercury in some ... // There were state wide tests conducted in the ... women of child-bearing age should eat only one meal ... Environmental Protection Agency guidelines the mercury contamination in the ...
... pediatrics at the Medical College of Wisconsin said that adult ... ,Both have different levels of chemicals (enzymes) in their ... in concentration with age. ,Hence this study suggests ... the young. ,This plays a vital role because ...
... marked as the National Children's Dental Health Month and ... widespread use of fluorides and school water // fluoridation ... However, it must be pointed out that the problem ... ,Baby Bottle Tooth Decay affects more infants ...
... International Journal of Cancer on February 17, 2006 tries to ... the level of physical activity in women. // The prospective ... link. ,Experts felt that since exercise is known ... the gastrointestinal transit time, it might also play a constructive ...
... solid organ. In UK there is an increase in demand as ... who do not receive transplants.// ,Hence it was decided ... of organs by as much as 20%. This was reported in ... supply of human organs for transplantation. , ,In general ...
Cached Medicine News:Health News:Rise in Mercury Levels in Supermarket Fish 2Health News:Women, Exercise and Colon Cancer 2
Developed specifically for the 5000/5500 ultrasound consoles....
Super High Density, multi-frequency, phased array burr hole transducer. Excellent for taking biopsy samples and shunt placements....
This unique tiny transducer can be very helpful in tight situations like during a carotid endardarectomy procedure....
... Penetration Steered Linear Peripheral Vascular transducer, with ... MHz. It is our newest vascular ... 4 different settings to optimize imaging of ... color and Doppler sensitivity of this transducer ...
Medicine Products: